CJC-1295 + Ipamorelin (Blend)

Overview

CJC-1295 + Ipamorelin is a synergistic peptide blend combining a growth hormone-releasing hormone (GHRH) analog with a selective growth hormone secretagogue. The combination targets two distinct but complementary pathways in the GH axis, producing amplified and more physiological growth hormone release than either peptide alone.

Mechanism of Action

CJC-1295 acts as a GHRH analog that stimulates pituitary somatotroph cells to produce and release GH. Ipamorelin is a selective ghrelin receptor (GHS-R) agonist that triggers GH secretion through a separate signaling pathway. When combined, GHRH provides the "accelerator" signal while the ghrelin mimetic lowers the release threshold, resulting in a robust but physiologically patterned GH pulse. Ipamorelin is notably selective, avoiding the cortisol and prolactin spikes associated with less specific secretagogues like GHRP-6.

Research Context

This combination is one of the most commonly used GH secretagogue protocols in the research community. Studies have examined its effects on lean body mass, sleep quality, recovery markers, and body composition. The synergy between GHRH and GHRP pathways is well-documented in endocrinology literature.

Key Research Areas

Considerations for Researchers

Blend ratios vary by vendor (commonly 1:1 or 2:1 CJC:Ipamorelin by weight). Verify the exact ratio and total peptide content per vial. Both peptides are stable when lyophilized. Reconstitute with BAC water. Evening administration aligns with natural GH pulsatility.